Linked inTwitterFacebookSubscribe to Halcyon Headlines Feed

Part consultancy, part thinktank, part social enterprise, Halcyon helps you prepare for and respond to personal, organisational and societal change.

Halcyon's forthcoming 52:52:52 campaign on Twitter will help you address 52 issues with 52 responses over 52 weeks.

To be a catalyst is the ambition most appropriate for those who see the world as being in constant change, and who, without thinking that they control it, wish to influence its direction - Theodore Zeldin

CRISPR

On CRISPR

Genetics

 

40%: The percentage of patients reported to have responded to one of the most advanced CRISPR cancer therapy studies to be tested in China. China is far ahead of the US in CRISPR cancer studies due to its less stringent approval requirements, but the US and Europe are set to see their first human trials of the gene-editing technique this year. With potentially transformative implications across medicine, agriculture, and even chemical products, CB Insights' 5,200-word CRISPR deep dive unpacks the science behind the technology, its applications, controversies it’s stirred up, and where CRISPR may take us next.